NRx Pharmaceuticals, Inc. today announced that it has obtained approximately $11 million in unsecured debt financing (the “Note”) from Streeterville Capital, LLC, a Utah limited liability company.
NRx Pharmaceuticals, Inc. today announced its Chief Executive Officer, Stephen Willard, and other executive leaders will be presenting an update to the company’s business at the H.C. Wainwright & Co. 24th Annual Global Investment Conference.
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. today announced that they have agreed to a tentative settlement of their pending litigation. The parties have agreed to work collaboratively to finalize the settlement within the next 30 days.
NRx Pharmaceuticals, Inc. today announced its financial results for the second quarter of 2022 and provided a business and clinical update.
NRx Pharmaceuticals, Inc. today announced that management will report second quarter 2022 financial results prior to the market open on August 15, 2022.
NRx Pharmaceuticals, Inc. today announced the appointment of Stephen Willard, as its Chief Executive Officer and a member of the Company’s Board of Directors.
NRx Pharmaceuticals, Inc. today announced that the US Food and Drug Administration (FDA) has declined to issue an Emergency Use Authorization (EUA) for ZYESAMI® (aviptadil) for a sub-group of patients that in addition to ZYESAMI®, also received Remdesivir and continued to progress.
NRx Pharmaceuticals, Inc. today announced its interim Chief Executive Officer, Robert Besthof, and other executive leaders will be presenting a virtual update to the company’s business via webcast at the H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond.
NRx Pharmaceuticals, Inc. is pleased to announce that on June 13, 2022, the plaintiffs in the securities class action lawsuit captioned “Dal Bosco v. NRx Pharmaceuticals, Inc. et al.” filed a notice in the U.S. District Court for the District of Delaware voluntarily dismissing the action against NRx Pharmaceuticals and its former officers. The dismissal was made without prejudice.
NRx Pharmaceuticals, Inc. today announced that the FDA denied the Breakthrough Therapy designation (BTD) request for ZYESAMI® (aviptadil) and emphasizes focus on its NRX-101 BTD compound for Bipolar Depression associated with Suicidality.
